Skip to main navigation Skip to search Skip to main content

Real world drug utilization patterns in the first years following a relapsing-remitting multiple sclerosis diagnosis

  • Dutch-MSR consortium
  • , P C G Molenaar*
  • , D L Weir
  • , E P J Arnoldus
  • , E A C Beenakker
  • , R P M van den Bos
  • , J J J van Eijk
  • , C Feenstra
  • , B M van Geel
  • , D J Heersema
  • , E Hoitsma
  • , K M Horvath
  • , J Killestein
  • , J J Kragt
  • , C E P van Munster
  • , A H W J M Snoeijen
  • , B H A Wokke
  • , W G Goettsch
  • , E M M Strijbis
  • , J W K de Beukelaar
  • N F Kalkers, B A de Jong
*Corresponding author for this work
  • MS Center Amsterdam
  • Elisabeth Tweesteden Hospital
  • Neurology News International
  • Jeroen Bosch Hospital
  • Alrijne Hospital
  • Amphia Hospital
  • MS Center ErasMS
  • Albert Schweitzer Hospital

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

BACKGROUND: Real-world drug utilization studies provide valuable insights into the treatment of relapsing-remitting multiple sclerosis (RRMS). As treatment dynamics in the Dutch context are limited, we studied drug utilization patterns in the first two years following a RRMS diagnosis in the Netherlands.

METHODS: People diagnosed with RRMS between 2016 and 2022 were included from the Dutch Multiple Sclerosis Registry, a registry-based observational study. Disease modifying therapies (DMTs) were categorized as low-, moderate- or high-efficacy. Initiation, discontinuation, reasons for discontinuation, and switches in the first two years post-diagnosis were evaluated. We calculated proportions with 95% confidence intervals (CI).

RESULTS: We included 806 PwMS. 2-year discontinuation was highest for low- (51%, CI: 45-57) and moderate-efficacy (37%, CI: 32-42) DMTs, mainly due to adverse events or insufficient efficacy. Of those switching from these therapies, 26% (CI: 21-33) switched to low-efficacy and 37% (CI: 30-44) to moderate-efficacy therapies, of which 32% (CI: 34-41) discontinued their second DMT. Anti-CD20 therapies were discontinued in 5% (CI: 2-15) of initiations. High-efficacy DMT use rose from 12% (CI: 10-15) at initiation to 29% (CI: 26-33) at year two.

CONCLUSION: Our results indicate high risks of discontinuation of low- and moderate-efficacy DMTs, in contrast to low risk of discontinuation of anti-CD20 therapies. These findings may give further direction to research on finding the optimal treatment strategy and may inform health care providers in the Netherlands.

Original languageEnglish
Article number107268
JournalMultiple Sclerosis and Related Disorders
Volume112
Early online date23 May 2026
DOIs
Publication statusPublished - Aug 2026

Bibliographical note

Publisher Copyright:
© 2026 The Authors

Funding

Members of the Dutch Multiple Sclerosis Registry consortium are: E.P.J. Arnoldus, Neurology, Elisabeth-TweeSteden Hospital, Tilburg, The Netherlands, E.A.C. Beenakker, Neurology, Frisius MC, Leeuwarden, The Netherlands, J.W.K. de Beukelaar, Neurology, Albert Schweitzer Hospital, Dordrecht, The Netherlands, P.A.D. Bouma, Neurology, Tergooi Hospital, Hilversum, Blaricum and Weesp, The Netherlands, W.H. Bouvy, Diakonessenhuis, Neurology, Utrecht, The Netherlands, J.J.J. van Eijk, Neurology, Jeroen Bosch Hospital, ‘s-Hertogenbosch, The Netherlands, C. Feenstra, Neurology, Flevoziekenhuis, Almere, The Netherlands, E. Eggink, Neurology, Gelre Hospital, Zutphen, The Netherlands, B.M. van Geel, Neurology, Noordwest Ziekenhuisgroep, Alkmaar, The Netherlands, O.H.H. Gerlach, Neurology, Academisch MS centrum Zuyd, Zuyderland Medical Center, Sittard-Geleen, The Netherlands, J.A.B. van Genugten, Neurology, Ziekenhuisgroep Twente, Almelo and Hengelo, The Netherlands, D.J. Heersema, Neurology, UMC Groningen, Groningen, The Netherlands, M.C.E. Hermans, Neurology, VieCurie Medical Center, Venlo, The Netherlands, E. Hoitsma, Neurology, Alrijne Hospital, Leiderdorp, The Netherlands, K.M. Horvath, Neurology, Treant Zorggroep, Hoogeveen, Stadskanaal and Emmen, The Netherlands, E.L.J. Hoogervorst, Neurology, St. Antonius Hospital, Utrecht, the Netherlands, B.A. de Jong, The Netherlands, MS Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam UMC location VUmc, Amsterdam, The Netherlands, N.F. Kalkers, OLVG, Amsterdam, The Netherlands, M.H. Klieverik, Neurology, Meander Medical Center, Amersfoort, The Netherlands, J.J. Kragt, Neurology, Reinier de Graaf Gasthuis, Delft, The Netherlands, M.L. van der Meer, Neurology, Amstelland Hospital, Amstelveen, The Netherlands, J.F. Meilof, Neurology, Martini Hospital, Groningen, the Netherlands, T. Mondria, Neurology, Antonius Hospital, Sneek, The Netherlands, C.E.P. van Munster, Neurology, Amphia Hospital, Neurology, Breda, The Netherlands, J.M. Nielsen, Neurology, Ommelander Hospital, Scheemda, The Netherlands, W. Onstenk, Neurology, Deventer Medical Center, Deventer, the Netherlands, M.T.J. Peeters, Neurology, Máxima Medical Center, Veldhoven, the Netherlands, E.E. van ’t Riet, Neurology, Wilhelmina Hospital, Assen, the Netherlands, L.C. van Rooij, Neurology, Maasstad Hospital, Rotterdam, The Netherlands, A.H.W.J.M. Snoeijen, Neurology, Elkerliek, Neurology, Helmond, The Netherlands, W. van Steenbergen, Neurology, Frisius MC, Heerenveen, The Netherlands, H.J. Weitenberg, Neurology, Nij Smellinghe Hospital, Drachten, The Netherlands M.P.E. Zeinstra, Neurology, Isala, Meppel, The Netherlands.

Funders
Jeroen Bosch Hospital
UMC Groningen
St. Antonius Ziekenhuis
M.C.E. Hermans
VieCurie Medical Center

    Keywords

    • Disease modifying therapies
    • Drug utilization patterns
    • Real-world data
    • Registry
    • Relapsing-remitting multiple sclerosis

    Fingerprint

    Dive into the research topics of 'Real world drug utilization patterns in the first years following a relapsing-remitting multiple sclerosis diagnosis'. Together they form a unique fingerprint.

    Cite this